BRCA1 oncogenic variants

About

Biomarker type: Somatic variant

Gene context: BRCA1

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (2) HC (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Olaparib
FDA (2) HC (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
FDA (2) HC (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib
HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone